市場調查報告書
商品編碼
1351541
血管閉合裝置市場規模 - 依裝置類型(主動血管閉合裝置、被動血管閉合裝置)、按通路(股骨、橈動脈)、依最終用途、預測,2023 年至 2032 年。Vascular Closure Device Market Size - By Device Type (Active Vascular Closure Devices, Passive Vascular Closure Devices), By Access (Femoral, Radial), By End-use, Forecast, 2023 - 2032. |
在血管閉合技術持續進步的推動下,2023 年至 2032 年全球血管閉合裝置市場規模將以 6.5% 的複合年成長率成長。血管閉合裝置設計和技術的不斷進步是推動力。製造商正在開發安全性更高、易於使用且降低併發症發生率的設備。
例如,2023 年 3 月,Vivasure Medical 獲得 FDA 試驗器械豁免 (IDE) 許可,標誌著其 PerQseal 器械的臨床研究向前邁出了重要一步。為了支持開發這種旨在解決大口徑動脈血管封堵中出血併發症的創新封堵系統,該公司從Haemonetics Corp 獲得了3000 萬歐元(約3200 萬美元)的戰略投資。這些創新旨在滿足特定需求不同患者群體和臨床場景的研究,這將有助於增強未來十年的產業前景。
整個血管閉合裝置市場根據裝置類型、通路、最終用途和地區進行分類。
2023-2032 年,被動血管閉合裝置產業將呈現 6.4% 的成長率。被動血管閉合裝置由於其微創性質並且能夠減少涉及動脈穿刺的手術中的併發症,因此在醫療領域越來越受歡迎。這些設備提供了一種方便有效的方法來實現止血,無需主動手動壓迫,從而縮短恢復時間,減少患者不適,並改善患者治療結果,最終推動它們在醫療保健專業人員中得到越來越多的採用。
在通路方面,到2032年,股動脈段血管閉合裝置的市佔率複合年成長率將達到6.6%。股動脈相對較大且容易進入,使其適合廣泛的介入性手術。 VCD 可以更有效地部署在股骨通路中,確保穿刺部位安全閉合,降低出血等併發症的風險,並使患者比其他接入點更快康復。這使得股動脈通路成為許多臨床場景中 VCD 應用的首選。
門診手術中心可能會主導血管閉合器械行業的最終使用格局,並在2023 年至2032 年間呈現6.4% 的複合年成長率。ASC 為包括血管介入治療在內的許多門診手術提供了傳統醫院的經濟高效的替代方案。血管閉合裝置對於最大限度地減少術後併發症和促進患者更快出院至關重要,符合 ASC 模型的效率和患者便利性目標。隨著 ASC 中進行的微創血管手術數量的增加,導致這種情況下對這些設備的需求不斷成長。
歐洲血管閉合器械產業正在經歷大幅成長,2023-2032 年複合年成長率將達到 6.3%。歐洲人口老化不斷加劇,導致心血管手術增加。促進病人安全的嚴格法規和先進醫療技術的採用推動了對更安全、更有效的閉合方法的需求。此外,醫療保健專業人員意識的提高以及該地區主要市場參與者的存在也有助於該行業在歐洲的強勁成長。
Global Vascular Closure Device Market size will expand at 6.5% CAGR from 2023 to 2032, driven by consistent advancements in vascular closure technologies. Continuous advancements in the design and technology of vascular closure devices are a driving force. Manufacturers are developing devices with improved safety profiles, ease of use, and reduced complication rates.
For instance, in March 2023, Vivasure Medical was granted FDA investigational device exemption (IDE) clearance, marking a significant step forward in its clinical study of the PerQseal device. To support the development of this innovative closure system designed to address bleeding complications in large-bore arterial vessel closure, the company secured a strategic investment of €30 million (~US$32 million) from Haemonetics Corp. These innovations aim to address the specific needs of different patient populations and clinical scenarios, which will help strengthen the industry outlook over the next ten years.
The overall vascular closure device market is categorized based on device type, access, end-use, and region.
The passive vascular closure device industry will demonstrate a 6.4% growth rate over 2023-2032. Passive vascular closure devices are gaining popularity in the medical field due to their minimally invasive nature and ability to reduce complications in procedures involving arterial punctures. These devices offer a convenient and effective way to achieve hemostasis without the need for active manual compression, leading to shorter recovery times, decreased patient discomfort, and improved patient outcomes, ultimately driving their increasing adoption among healthcare professionals.
In terms of access, the vascular closure device market share from the femoral segment will record 6.6% CAGR through 2032. The femoral artery is relatively large and accessible, making it suitable for a wide range of interventional procedures. VCDs can be deployed more effectively in femoral access, ensuring secure closure of the puncture site, reducing the risk of complications such as bleeding, and enabling faster patient recovery than other access points. This makes femoral access a preferred choice for VCD applications in a number of clinical scenarios.
Ambulatory Surgical Centers could dominate the end-use landscape of the vascular closure device industry and exhibit a 6.4% CAGR between 2023 and 2032. ASCs offer cost-effective alternatives to traditional hospitals for many outpatient procedures, including vascular interventions. Vascular closure devices are crucial in minimizing post-procedure complications and facilitating quicker patient discharge, aligning with the ASC model's goals of efficiency and patient convenience. This, along with the increasing volume of minimally invasive vascular procedures performed in ASCs, contributes to the rising demand for these devices in this setting.
Europe vascular closure device industry is experiencing substantial growth and will expand at 6.3% CAGR throughout 2023-2032. Europe has a growing aging population, leading to increased cardiovascular procedures. Stringent regulations promoting patient safety and the adoption of advanced medical technologies have fueled the demand for safer and more efficient closure methods. Additionally, expanding awareness among healthcare professionals and the presence of key market players in the region contribute to the industry's robust growth in Europe.